IDEXX Laboratories saw its shares climb 3.4% to $582 in premarket trading on Tuesday following an upward revision to its full-year profit and revenue outlook. The animal diagnostics company adjusted both earnings-per-share and top-line guidance for 2026.
The company now expects 2026 profit in a range of $14.45 to $14.90 per share, up from its prior forecast of $14.29 to $14.80 per share. That revised EPS range should be read alongside analyst expectations of $14.51 per share, as reported by LSEG data.
IDEXX also raised its revenue projection for 2026 to a range of $4.68 billion to $4.76 billion, compared with the previous outlook of $4.63 billion to $4.72 billion. The tightened and elevated ranges for both profit and revenue reflect the company updating its full-year financial targets.
Operationally, IDEXX reported first-quarter revenue of $1.14 billion, which topped analysts' estimates of $1.11 billion. That quarterly result is the same figure reported by the company and the comparison estimate is taken from the analyst consensus cited above.
Despite the guidance raise and the quarterly beat, IDEXX shares remain below their levels at the start of the year. As of the close of trading on Monday, the stock was down 16.8% year-to-date.
Market reaction was focused in premarket trading, where the share price moved higher following the updated guidance. The company-provided ranges for 2026 profit and revenue are presented as ranges rather than single-point forecasts, indicating variability within the company outlook.
Investors balancing the updated forecasts and the quarterly revenue beat will weigh those items against the year-to-date share price decline noted above. The EPS guidance range compares with the analyst midpoint provided by LSEG data, and the revenue guidance range was raised relative to the prior company outlook.
In summary, IDEXX raised both its 2026 EPS and revenue guidance and reported a first-quarter top line that exceeded analyst expectations. The stock responded positively in early trading, while its performance year-to-date remained negative as of the most recent close.